More news on our GLP-1 pill in development: positive data from two additional late-stage trials in adults with type 2 diabetes. Read more: https://t.co/jlWcTEc9QN

People with #UlcerativeColitis need treatments that offer a chance for long-term remission and relief from disruptive symptoms like bowel urgency. Learn more about positive 4-year data for an approved Lilly medicine, presented at #UEGWeek: https://t.co/DROUNZObtv

Game-changing science is a collaborative effort. Today we opened Lilly Gateway Labs in San Diego, our fifth shared innovation center worldwide. Together, we can accelerate the next generation of breakthrough medicines. Read more: https://t.co/tA3FIqOmzC. #WeAreLilly

The @US_FDA approved a new oral therapy for people living with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2–), estrogen receptor 1-mutated (ESR1m) #MetastaticBreastCancer. Learn more: https://t.co/kRc7w5KGap

We’ve announced plans to open a new manufacturing site in Houston, the second of 4 new locations coming to the U.S. See the details of the $6.5 billion facility, which will bring an expected 4,615 jobs and help boost domestic medicine manufacturing: https://t.co/PJtNrpL1Si

More news today on our once-daily GLP-1 pill in development: Positive results of a late-stage clinical trial comparing our investigational medicine to another oral GLP-1. Read more: https://t.co/rIex398pRg

Obesity affects more than 1 billion people worldwide. Published today in @NEJM, the full results of a positive late-stage clinical trial of our investigational obesity pill. https://t.co/WcDOlcMyNM

New positive topline results announced from our Phase 3 #BloodCancer study in people living with chronic lymphocytic leukemia (#CLL). https://t.co/RT94aLL2BQ

KRAS are the most common mutations in non-small cell lung cancer (#NSCLC), with G12C mutations present in ~13% of cases. The @FDA granted Breakthrough Therapy designation for our investigational treatment. Updated data coming at #WCLC25. Learn more: https://t.co/F6C4iMR2AI

Results are in from our latest positive late-stage clinical trial of a once-daily pill for obesity. Next step: submission to regulators, putting us one step closer to making it broadly available, if approved. Read more: https://t.co/nyIk03xKoh

Lilly supports the U.S. administration’s goal of ensuring fair global contributions to the cost of American innovation. Read our policy statement on how we are helping lead the way: https://t.co/mfYOqIC3mA

Through the first half of the year, we’re making progress on our goal to help more people have a chance at better health. Read more about our Q2 results: https://t.co/APRO56YNhd

A once-a-day pill to treat obesity could be a game-changer. Today we announced positive results of a late-stage clinical trial studying a once-daily oral medicine for obesity. Read more: https://t.co/nsf4ACtbVD

News in diabetes: positive results of a trial studying the effect of our incretin medicines on major cardiovascular events in people with type 2 diabetes. Read more: https://t.co/7fl9qXgKga

Positive topline results announced from one of our Phase 3 #BloodCancer studies. Learn more here: https://t.co/XoELQ0C2m8

What if science could completely change the treatment of cardiovascular disease—from chronic care to a one-and-done treatment? Today we officially acquired Verve Therapeutics, expanding our pipeline of cardiometabolic health medicines. https://t.co/GgKMCxi2oY

Today at the @AmDiabetesAssn meeting: detailed results of multiple late-stage studies of an investigational therapy for type 2 diabetes that could simplify insulin management. Read more: https://t.co/hrc24XOnxN #ADA2025

Results of the first late-stage clinical study of a potential new type 2 diabetes pill were presented today at the @AmDiabetesAssn meeting and published in the @NEJM. Read more: https://t.co/0pRxBqxYrA

New today: the full results of a study comparing our obesity medicine to another therapy were published in the @NEJM and presented at the European Congress on Obesity. Read more: https://t.co/8MxDZmNxgS

We’re on our way to helping more people than ever before. For more information, click here: https://t.co/d29NHpb4zz